The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose-finding trial of cabozantinib (cabo) and trifluridine/tipiracil (FDT/TPI) in metastatic colorectal carcinoma (mCRC).
 
Farshid Dayyani
Employment - Roche (I)
Consulting or Advisory Role - Array BioPharma; Eisai; Exelixis; Genentech/Roche; QED Therapeutics; Signatera
Speakers' Bureau - Amgen; Deciphera; Eisai; Exelixis; Genentech/Roche; ipsen; Natera; SERVIER; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Jasmine Balangue
No Relationships to Disclose
 
Jennifer Brooke Valerin
No Relationships to Disclose
 
Jason A. Zell
No Relationships to Disclose
 
Thomas H Taylor
No Relationships to Disclose
 
May Thet Cho
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Basilea; Eisai; Exelixis; Genentech/Roche; Ipsen; QED Therapeutics; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; Helsinn Therapeutics; natera; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); incyte (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune